Perimenopause and menopause affect every system in your body, not just your reproductive hormones. Cardiovascular risk increases. Thyroid problems become more common. Bone density declines. Metabolic efficiency drops. A single FSH test does not capture any of this.
Most GPs will check FSH if you report menopausal symptoms. If it is elevated, you are told you are menopausal. If it is normal, you are told you are not. This binary approach misses nearly everything that matters.
Perimenopause is a 2 to 10 year transition. During it, FSH fluctuates. A single normal FSH result does not mean you are not perimenopausal. And even when FSH confirms menopause, it tells you nothing about how menopause is affecting your cardiovascular system, your thyroid, your bones, your metabolism, or your mental health. Those are the systems where menopause causes the most damage if left unmonitored.
Oestradiol declines, progesterone drops, FSH rises. But the pattern matters more than the numbers. LH and FSH together reveal ovarian reserve status. Progesterone tested mid-cycle confirms whether ovulation is still occurring. Testosterone declines too, affecting energy, libido, and muscle tone. SHBG shifts alter how much of each hormone is bioavailable. A comprehensive hormone panel shows the full transition picture, not just a single FSH snapshot.
Oestrogen provides cardiovascular protection before menopause. As oestradiol declines, that protection fades. LDL cholesterol rises. ApoB increases. Triglycerides shift. Inflammatory markers can elevate. Lp(a), which is genetically fixed, becomes more clinically relevant as other protective factors decline. Testing ApoB and Lp(a) at the start of perimenopause establishes your pre-transition cardiovascular baseline. Testing them again post-menopause shows how much risk has shifted. The NHS does not test either. Advanced lipid testing guide.
Thyroid dysfunction becomes more common during and after menopause. Hashimoto's thyroiditis prevalence peaks in women aged 45 to 55. The symptoms of hypothyroidism (fatigue, weight gain, brain fog, low mood, cold intolerance, dry skin) overlap almost entirely with menopausal symptoms. Without full thyroid testing (TSH, Free T3, Free T4, and antibodies), there is no way to distinguish whether symptoms are hormonal, thyroid, or both. Many women attributed their symptoms to menopause for years before discovering an underactive thyroid was the real driver. Thyroid testing guide.
Oestrogen maintains bone density. After menopause, bone loss accelerates significantly, with the fastest decline in the first 5 to 7 years post-menopause. Calcium, vitamin D, phosphate, ALP, and parathyroid hormone (PTH) together assess bone turnover and mineral status. Low vitamin D with elevated PTH suggests the body is pulling calcium from bones to maintain blood calcium levels. Catching this early opens a window for supplementation and lifestyle intervention before a DEXA scan shows osteopenia or osteoporosis.
Insulin sensitivity declines after menopause. Visceral fat increases. The risk of type 2 diabetes rises sharply. HbA1c and fasting glucose only catch this once it is advanced. Fasting insulin and HOMA-IR detect metabolic dysfunction years earlier. Testing them alongside the hormonal transition reveals whether menopause is accelerating metabolic decline and what to do about it. Metabolic testing guide.
Iron dynamics shift at menopause. Menstrual blood loss stops, so ferritin often rises. But iron overload can develop in some post-menopausal women, particularly those with undiagnosed haemochromatosis genes. Meanwhile, B12 absorption declines with age, vitamin D deficiency is endemic in the UK, and magnesium depletion affects sleep and anxiety. Full nutritional screening catches the deficiencies that compound menopausal symptoms. Iron testing guide.
Periods become irregular. Symptoms fluctuate. Hormones swing unpredictably. FSH may be normal one month and elevated the next. This is the most frustrating phase because a single blood test can look "normal" while you feel anything but.
What to test: Full hormones (FSH, LH, oestradiol, progesterone, testosterone, SHBG, cortisol, DHEA-S), full thyroid with antibodies, ApoB, HbA1c, insulin, vitamin D, B12, full iron studies, and hs-CRP. This establishes your transition baseline and rules out thyroid dysfunction as a symptom driver.
When to test: Day 2 to 5 of your cycle if still having periods. Any day if periods have stopped or are very irregular. Retest every 6 to 12 months to track the transition.
Hormones have settled at their new baseline. The transition symptoms may ease, but the cardiovascular, metabolic, and bone health risks are now at their highest. This is when monitoring shifts from "what is happening" to "what damage is accumulating."
What to test: Everything above plus Lp(a) (if never tested), bone markers (calcium, ALP, PTH, phosphate), cystatin C (kidney function), and tumour markers (CA-125, CA 15-3). Annual comprehensive testing becomes your primary health surveillance tool.
When to test: Any day. No cycle timing needed. Annual at minimum, 6-monthly if on HRT or managing risk factors.
HRT replaces hormones your body is no longer producing. But "replacement" does not mean your levels are automatically optimal. Too little and symptoms persist. Too much and risks increase. Regular blood testing ensures your HRT is doing what it should.
Confirms whether your dose is achieving therapeutic levels. Optimal on transdermal HRT is typically 200 to 600 pmol/L. Below 200 suggests underdosing. Your report flags where you sit.
Essential to monitor if you have a uterus. Progesterone protects the endometrium from unopposed oestrogen. Inadequate progesterone on HRT increases endometrial cancer risk.
Increasingly prescribed alongside HRT for libido, energy, and mood. SHBG context is essential because oestrogen HRT raises SHBG, which can bind testosterone and reduce its effectiveness.
Oral oestrogen HRT increases thyroid-binding globulin, which can alter how thyroid hormones are distributed. Women on levothyroxine may need dose adjustments after starting HRT. Full thyroid monitoring catches this.
Oral HRT is metabolised through the liver. Monitoring ALT, AST, and GGT ensures liver health is maintained. Transdermal HRT bypasses the liver and has a different risk profile.
HRT affects lipid profiles. Oral oestrogen raises HDL and triglycerides. Transdermal has a more neutral effect. ApoB monitoring tracks whether your net cardiovascular risk is improving or worsening on your regimen.
Testing timing on HRT: If on transdermal oestrogen or testosterone, test the morning before your next application. If on oral HRT, test 12 hours after your last dose. Tell us your HRT type and dose in the lifestyle quiz so your report adjusts interpretation.
This is the most commonly missed diagnosis in women over 40. The symptom overlap between menopause and hypothyroidism is almost complete: fatigue, weight gain, brain fog, low mood, anxiety, poor sleep, dry skin, hair thinning, cold intolerance.
If your GP tests FSH and it is elevated, the symptoms are attributed to menopause. If FSH is normal, you are told nothing is wrong. In neither scenario is thyroid function checked in depth. Meanwhile, Hashimoto's thyroiditis peaks in prevalence during exactly the same age window as perimenopause.
The result: thousands of women are treated for menopause when their thyroid is the primary driver, or are told they are "fine" when subclinical hypothyroidism is causing their symptoms, or have both conditions simultaneously and only one is being managed.
TrueVitals tests full thyroid (TSH, Free T3, Free T4, and antibodies) alongside complete reproductive hormones in every panel. Your report identifies whether your symptoms are hormonal, thyroid, or a combination, and gives you the data to take to your GP or menopause specialist. Full thyroid testing guide.
FSH above 30 IU/L with low oestradiol on two tests 4 to 6 weeks apart is the standard biochemical confirmation. But confirmation is only part of the picture. Comprehensive testing reveals how menopause is affecting your cardiovascular, thyroid, metabolic, and bone health, which matters more for long-term outcomes.
Perimenopause is primarily diagnosed by symptoms and menstrual changes. Blood tests can support the picture (rising FSH, declining oestradiol, low progesterone) but hormones fluctuate significantly during this phase. A single normal result does not rule it out. A comprehensive panel that also checks thyroid, metabolic, and cardiovascular markers is more useful than chasing a single confirmatory FSH number.
During perimenopause, every 6 to 12 months to track the transition and monitor cardiovascular and metabolic shifts. Post-menopause, annually at minimum. If on HRT, every 6 months to ensure levels are therapeutic. Over-40s testing guide.
The NHS will test FSH if clinically indicated, but does not routinely test the full hormonal panel, thyroid antibodies, ApoB, insulin, or bone markers as part of menopause care. A private comprehensive blood test provides significantly deeper data for both you and your prescribing clinician. NHS vs private comparison.
The Ultimate panel (115 biomarkers for women, £349) is the recommended choice. It includes all reproductive hormones, full thyroid with antibodies, ApoB, Lp(a), insulin, full iron studies, bone markers, tumour markers (CA-125, CA 15-3), and complete urinalysis. For maximum depth including autoimmune profiling and digestive health, the Signature panel (200+, £799) goes further. Compare all panels.
115 biomarkers for women. Hormones, thyroid, cardiovascular, metabolic, bone health, and cancer screening. AI-powered cross-system analysis. £349.
.png)